Colistin Pharmacokinetics in Pediatric Cancer Patients in Egypt | ||||
| Archives of Pharmaceutical Sciences Ain Shams University | ||||
| Article 4, Volume 6, Issue 2, December 2022, Page 208-220 PDF (754.32 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/aps.2022.166621.1099 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Yosr Abou Sedira1; Lamia El Wakeel   2; Mervat Omran3; Iman Sidhom4; Samia Shouman3
| ||||
| 1Department of Clinical Pharmacy, National Cancer Institute, Cairo University, Cairo, Egypt | ||||
| 2Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo 11566, Egypt | ||||
| 3Pharmacology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt | ||||
| 4Department of Pediatric Oncology, National Cancer Institute, Cairo University, Cairo, Egypt Pediatric Oncology department, Children's Cancer Hospital Egypt | ||||
| Abstract | ||||
| Background: Colistin has been reintroduced to clinical practice after the emergence of multidrug-resistant gram-negative (MDR-GN) and failure of other antibiotics. Pharmacokinetics and pharmacodynamic data in pediatric population are scarce. This study aimed to highlight the pharmacokinetics of 2 colistin doses, 2.5 and 5mg/kg/day, in febrile neutropenia pediatrics cancer patients regarding patient outcomes. Patients and methods: In a prospective, comparative study, patients suffering from MDR-GN infection were randomly recruited to receive either 2.5 or 5mg/kg/day colistin doses. The demographic, microbiological, and treatment outcomes were collected before and after treatment. Colistin levels were determined using HPLC/MS/MS. Peak, trough, area under the concentration-time curve (AUC24), and the ratio of AUC24 to the minimum inhibitory concentration (AUC24/MIC) were assessed. Results. Clinical cure was achieved in 14(77.8%) cases in the Low-Dose (LD) group vs. 13(81.3%) in the High-Dose (HD) group. Four (25%) patients vs. 4(33.3%) in the LD and HD group (P=0.69) attained an optimal plasma AUC24/MIC, respectively, while the therapeutic level of colistin was reached in all patients in the LD group compared to 14/16 (87.5%) in the HD group. Microbiological eradication was achieved in (93.8%) and (91.6%) of patients in the LD and HD groups, respectively. However, the median time to clearance was significantly lower in the LD group, 4 days vs. 7 days in the HD group (P=0.022). Conclusion: The current study suggests that the LD may be as efficacious and safe as the HD in treating MDR-GN infection. However, LD colistin was associated with a shorter clearance time than HD colistin. | ||||
| Keywords | ||||
| Colistin; pediatric cancer patients; MDR gram-negative infection; plasma concentration; pharmacokinetics | ||||
|
Statistics Article View: 266 PDF Download: 341 |
||||
